Clinical trial
Rosiglitazone to Reverse Metabolic Defects in Diabetes
NCT00094796 · National Heart, Lung, and Blood Institute (NHLBI), NIH · Completed
Key facts
| NCT number | NCT00094796 |
|---|---|
| Title | Rosiglitazone to Reverse Metabolic Defects in Diabetes |
| Official title | Evaluation of Rosiglitazone in Reversing Metabolic Defects of Pre-Diabetes and Type 2 Diabetes Mellitus |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type II, Insulin Resistance |
| Intervention type | Procedure |
| Interventions | Exercise cardiopulmonary metabolic testing, Skeletal muscle biopsy, Brachial artery reactivity testing |
| Enrollment | 70 |
| Start date | Oct 20, 2004 |
| Completion | Sep 3, 2008 |
| First posted | Oct 25, 2004 |
| Last update posted | Jul 2, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: